# Gynecologic Oncology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ada Lovelace (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI031-SYN-TD
- Date: 1851-06-16
- Fictional facility: St. Posthumous Health Center
- Fictional author: Beatrix Lindgren-Osei, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Constance Whitley-Adeyemi, MD

## Reason for consultation

Friable exophytic cervical mass with five months of abnormal bleeding and constant pelvic pain in a 35-year-old woman, biopsied today, with iron deficiency anemia. Please confirm the diagnosis, stage the disease, advise on treatment intent and options, and help with control of bleeding and pain. **S**

## History

Mrs. Lovelace, a 35-year-old mathematician, is seen at the request of Dr. Whitley-Adeyemi for a cervical mass found two weeks ago after five months of abnormal bleeding and pelvic pain. The bleeding is lighter since the first iron infusion but continues. Her pain averages 6 of 10 on oral morphine solution 5 mg about six times a day, without drowsiness; she stopped the opium tincture she had taken for two years. She has no cough, hemoptysis, bone pain, leg swelling, or urinary or bowel symptoms beyond opioid-related constipation. She has never had cervical screening. She does not wish to preserve fertility. She asked to be told the findings directly. **S**

## Examination

| System | Finding |
|---|---|
| General | Pale, alert, not sedated; blood pressure 106/66, pulse 92; ECOG performance status 1 |
| Lymph nodes | No supraclavicular or inguinal lymph node enlargement |
| Abdomen | Soft; mild suprapubic tenderness; no masses |
| Pelvis | Exophytic friable cervical tumor about 5 cm with light bleeding; left parametrial thickening not reaching the sidewall; vagina free; rectovaginal septum free |

BP 106/66 mmHg; pulse 92 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 54.2 kg; BMI 19.9 kg/m². All vital signs are synthetic.

## Data reviewed

Cervical biopsy: invasive adenocarcinoma, usual (HPV-associated) type, p16 diffusely positive, HPV 18 detected; PD-L1 combined positive score 5; mismatch repair proteins retained; HER2 immunohistochemistry 1+. Pelvic MRI a week ago: 5.2 cm endocervical tumor with left parametrial invasion, not reaching the sidewall, no hydronephrosis, an enlarged left external iliac node. FDG PET-CT five days ago: avid tumor, avid left pelvic and para-aortic nodes, six avid nodules in both lungs up to 1.4 cm, no bone or liver lesions. Hemoglobin 9.0 g/dL today, from 8.4; creatinine 0.66 mg/dL; ALT 17 U/L; TSH 1.9 mIU/L; HIV, hepatitis B and hepatitis C tests negative. Hemoglobin: 9 g/dL (low); Creatinine: 0.66 mg/dL; ALT: 17 U/L; TSH: 1.9 mIU/L; Free T4: 1.2 ng/dL; eGFR: 117 mL/min/1.73 m²; Pelvic pain, average over the past week (0 to 10): 6. All results are synthetic.

## Assessment

1. **Adenocarcinoma of the cervix, HPV 18 positive, FIGO 1843 stage IVB by imaging** (C53.0). The lung nodules and para-aortic nodes on PET-CT mean distant spread, stage IVB by imaging; because this decides that treatment is palliative rather than curative, a lung nodule should be biopsied to confirm it before systemic therapy. With PD-L1 combined positive score 5, the NCCN preferred first-line treatment is carboplatin or cisplatin with paclitaxel and pembrolizumab, with or without bevacizumab, based on KEYNOTE-826. I recommend carboplatin, for ease and less toxicity, and leaving out bevacizumab for now, because she is bleeding from the tumor and will have pelvic radiation, which raise the risks of hemorrhage and fistula. Cervical cancer is not part of a hereditary cancer syndrome, so germline testing is not indicated; the tumor biomarkers are complete for first-line and later choices. **S**
2. **Iron deficiency anemia from tumor bleeding** (D50.0). Bleeding will not stop without treating the tumor. A short course of palliative pelvic radiation controls bleeding in most patients within one to two weeks. Transfusion if hemoglobin falls below 7 to 8 g/dL or she has symptoms. **S**
3. **Cancer-related pelvic pain** (G89.3). Constant visceral and nociceptive pain from the tumor and parametrial spread, needing scheduled opioid therapy, which radiation and systemic treatment should also reduce. Her long prior use of opium tincture does not argue against opioids for cancer pain, but calls for clear, measured dosing, one prescriber, and attention to sedation, given her wish for a clear mind. **S**

## Recommendations

1. CT-guided biopsy of a lung nodule to confirm metastatic disease.
2. Palliative pelvic radiation, 20 Gy in 5 fractions, starting next week, for bleeding and pain.
3. Then carboplatin (AUC 5), paclitaxel 175 mg/m2 and pembrolizumab 200 mg every 3 weeks for six cycles, with pembrolizumab continuing as maintenance; no bevacizumab for now.
4. Blood counts, creatinine and ALT before each cycle; TSH and free T4 at baseline and every six weeks on pembrolizumab; restaging CT after four cycles.
5. No germline genetic testing.
6. Long-acting morphine 15 mg every 12 hours with morphine solution 5 mg as needed for breakthrough pain, a daily bowel regimen, naloxone, and one prescriber, under Dr. Whitley-Adeyemi with the palliative care team.
7. Specialist palliative care alongside treatment from today.
8. Complete intravenous iron; transfuse only below 7 to 8 g/dL or for symptoms.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Dr. Whitley-Adeyemi and I gave Mrs. Lovelace the diagnosis together, at her request, in plain words: the cancer has spread and cannot be cured, and treatment aims to stop the bleeding, ease the pain, control the cancer and help her live longer and well. She asked about treatment and its effects on her thinking, and chose radiation and chemotherapy with pembrolizumab. The palliative care team saw her the same afternoon. **S**

## Follow-up

Gynecologic oncology after the lung biopsy and before the first cycle, then before each cycle, with restaging after four cycles. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (2026), National Comprehensive Cancer Network
- Revised FIGO staging for carcinoma of the cervix uteri (Bhatla N, et al. Int J Gynaecol Obstet 2019;145:129-135) (2018), International Federation of Gynecology and Obstetrics
- Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826; Colombo N, et al. N Engl J Med 2021;385:1856-1867) (2021), New England Journal of Medicine
- Palliative Care for Patients With Cancer: ASCO Guideline Update (Sanders JJ, et al. J Clin Oncol 2024;42:2336-2357) (2024), American Society of Clinical Oncology
- Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline (Paice JA, et al. J Clin Oncol 2023;41:914-930) (2023), American Society of Clinical Oncology
- Patient-Clinician Communication: ASCO Guideline Update (Gilligan T, et al. J Clin Oncol 2026;44:1040-1057) (2026), American Society of Clinical Oncology
